. 2021 Aug;75(2):424-434.

doi: 10.1016/j.jhep.2021.03.013. Epub 2021 Apr 12.

A novel microRNA-based prognostic model outperforms standard prognostic models in patients with acetaminophen-induced acute liver failure

Collaborators, Affiliations

Collaborators

United States Acute Liver Failure Study Group:
W M Lee⁷, Anne M Larson⁷, Iris Liou⁷, Oren Fix⁸, Michael Schilsky⁹, Timothy McCashland¹⁰, J Eileen Hay¹¹, Natalie Murray¹², A Obaid S Shaikh¹³, Andres Blei¹⁴, Daniel Ganger¹⁴, Atif Zaman¹⁵, Steven H B Han¹⁶, Robert Fontana¹⁷, Brendan McGuire¹⁸, Raymond T Chung¹⁹, Alastair Smith²⁰, Robert Brown²¹, Jeffrey Crippin²², Edwin Harrison²³, Adrian Reuben²⁴, Santiago Munoz²⁵, Rajender Reddy²⁶, R Todd Stravitz²⁷, Lorenzo Rossaro²⁸, Raj Satyanarayana²⁹, Tarek Hassanein³⁰, Constantine J Karvellas³¹, Jodi Olson³², Ram Subramanian³³, James Hanje³⁴, Bilal Hameed³⁵, Ezmina Lalani³⁶, Carla Pezzia³⁶, Corron Sanders³⁶, Nahid Attar³⁶, Linda S Hynan³⁶, Valerie Durkalski³⁷, Wenle Zhao³⁷, Jaime Speiser³⁷, Catherine Dillon³⁷, Holly Battenhouse³⁷, Michelle Gottfried³⁷

Affiliations

¹ Institute of Liver Studies, King's College Hospital, London, UK.
² Division of Gastroenterology and Department of Critical Care Medicine, University of Alberta, Edmonton, Canada.
³ Department of Biostatistics and Data Science, Wake Forest School of Medicine, North Carolina, USA.
⁴ Hepato-neuro Laboratory, CRCHUM, Université de Montréal, Montréal, Canada.
⁵ Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Texas, USA.
⁶ Institute of Liver Studies, King's College Hospital, London, UK. Electronic address: varuna.aluvihare@kcl.ac.uk.
⁷ University of Washington, Seattle, WA, USA.
⁸ Swedish Medical Center, Seattle, WA, USA.
⁹ Yale University, New Haven, CT, USA.
¹⁰ University of Nebraska, Omaha, NE, USA.
¹¹ Mayo Clinic, Rochester, MN, USA.
¹² Baylor University Medical Center, Dallas, TX, USA.
¹³ University of Pittsburgh, Pittsburgh, PA, USA.
¹⁴ Northwestern University, Chicago, IL, USA.
¹⁵ University of Oregon, Portland, OR, USA.
¹⁶ University of California, Los Angeles, CA, USA.
¹⁷ University of Michigan, Ann Arbor, MI, USA.
¹⁸ University of Alabama, Birmingham, AL, USA.
¹⁹ Massachusetts General Hospital, Boston, MA, USA.
²⁰ Duke University Medical Center, Durham, NC, USA.
²¹ Cornell/Columbia University, New York, NY, USA.
²² Washington University, St Louis, MO, USA.
²³ Mayo Clinic, Scottsdale, AZ, USA.
²⁴ Medical University of South Carolina, Charleston, SC, USA.
²⁵ Albert Einstein Medical Center, Philadelphia, PA, USA.
²⁶ University of Pennsylvania, Philadelphia, PA, USA.
²⁷ Virginia Commonwealth University, Richmond, VA, USA.
²⁸ University of California Davis, Sacramento, CA, USA.
²⁹ Mayo Clinic, Jacksonville, FL, USA.
³⁰ University of California, San Diego, CA, USA.
³¹ University of Alberta, Edmonton, AB, USA.
³² University of Kansas, Kansas City, KA, USA.
³³ Emory, Atlanta, GA, USA.
³⁴ Ohio State University, Columbus, OH, USA.
³⁵ University of California San Francisco, CA, USA.
³⁶ The University of Texas Southwestern Administrative Group included Grace Samuel, USA.
³⁷ the Medical University of South Carolina Data Coordination Unit, USA.

PMID: 33857547
PMCID: PMC10668489
DOI: 10.1016/j.jhep.2021.03.013

A novel microRNA-based prognostic model outperforms standard prognostic models in patients with acetaminophen-induced acute liver failure

Oliver D Tavabie et al. J Hepatol. 2021 Aug.

. 2021 Aug;75(2):424-434.

doi: 10.1016/j.jhep.2021.03.013. Epub 2021 Apr 12.

Collaborators

United States Acute Liver Failure Study Group:
W M Lee⁷, Anne M Larson⁷, Iris Liou⁷, Oren Fix⁸, Michael Schilsky⁹, Timothy McCashland¹⁰, J Eileen Hay¹¹, Natalie Murray¹², A Obaid S Shaikh¹³, Andres Blei¹⁴, Daniel Ganger¹⁴, Atif Zaman¹⁵, Steven H B Han¹⁶, Robert Fontana¹⁷, Brendan McGuire¹⁸, Raymond T Chung¹⁹, Alastair Smith²⁰, Robert Brown²¹, Jeffrey Crippin²², Edwin Harrison²³, Adrian Reuben²⁴, Santiago Munoz²⁵, Rajender Reddy²⁶, R Todd Stravitz²⁷, Lorenzo Rossaro²⁸, Raj Satyanarayana²⁹, Tarek Hassanein³⁰, Constantine J Karvellas³¹, Jodi Olson³², Ram Subramanian³³, James Hanje³⁴, Bilal Hameed³⁵, Ezmina Lalani³⁶, Carla Pezzia³⁶, Corron Sanders³⁶, Nahid Attar³⁶, Linda S Hynan³⁶, Valerie Durkalski³⁷, Wenle Zhao³⁷, Jaime Speiser³⁷, Catherine Dillon³⁷, Holly Battenhouse³⁷, Michelle Gottfried³⁷

Affiliations

¹ Institute of Liver Studies, King's College Hospital, London, UK.
² Division of Gastroenterology and Department of Critical Care Medicine, University of Alberta, Edmonton, Canada.
³ Department of Biostatistics and Data Science, Wake Forest School of Medicine, North Carolina, USA.
⁴ Hepato-neuro Laboratory, CRCHUM, Université de Montréal, Montréal, Canada.
⁵ Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Texas, USA.
⁶ Institute of Liver Studies, King's College Hospital, London, UK. Electronic address: varuna.aluvihare@kcl.ac.uk.
⁷ University of Washington, Seattle, WA, USA.
⁸ Swedish Medical Center, Seattle, WA, USA.
⁹ Yale University, New Haven, CT, USA.
¹⁰ University of Nebraska, Omaha, NE, USA.
¹¹ Mayo Clinic, Rochester, MN, USA.
¹² Baylor University Medical Center, Dallas, TX, USA.
¹³ University of Pittsburgh, Pittsburgh, PA, USA.
¹⁴ Northwestern University, Chicago, IL, USA.
¹⁵ University of Oregon, Portland, OR, USA.
¹⁶ University of California, Los Angeles, CA, USA.
¹⁷ University of Michigan, Ann Arbor, MI, USA.
¹⁸ University of Alabama, Birmingham, AL, USA.
¹⁹ Massachusetts General Hospital, Boston, MA, USA.
²⁰ Duke University Medical Center, Durham, NC, USA.
²¹ Cornell/Columbia University, New York, NY, USA.
²² Washington University, St Louis, MO, USA.
²³ Mayo Clinic, Scottsdale, AZ, USA.
²⁴ Medical University of South Carolina, Charleston, SC, USA.
²⁵ Albert Einstein Medical Center, Philadelphia, PA, USA.
²⁶ University of Pennsylvania, Philadelphia, PA, USA.
²⁷ Virginia Commonwealth University, Richmond, VA, USA.
²⁸ University of California Davis, Sacramento, CA, USA.
²⁹ Mayo Clinic, Jacksonville, FL, USA.
³⁰ University of California, San Diego, CA, USA.
³¹ University of Alberta, Edmonton, AB, USA.
³² University of Kansas, Kansas City, KA, USA.
³³ Emory, Atlanta, GA, USA.
³⁴ Ohio State University, Columbus, OH, USA.
³⁵ University of California San Francisco, CA, USA.
³⁶ The University of Texas Southwestern Administrative Group included Grace Samuel, USA.
³⁷ the Medical University of South Carolina Data Coordination Unit, USA.

PMID: 33857547
PMCID: PMC10668489
DOI: 10.1016/j.jhep.2021.03.013

Abstract

Background & aims: Acetaminophen (APAP)-induced acute liver failure (ALF) remains the most common cause of ALF in the Western world. Conventional prognostic models, utilising markers of liver injury and organ failure, lack sensitivity for mortality prediction. We previously identified a microRNA signature that is associated with successful regeneration post-auxiliary liver transplant and with recovery from APAP-ALF. Herein, we aimed to use this microRNA signature to develop outcome prediction models for APAP-ALF.

Methods: We undertook a nested, case-control study using serum samples from 194 patients with APAP-ALF enrolled in the US ALF Study Group registry (1998-2014) at early (day 1-2) and late (day 3-5) time-points. A microRNA qPCR panel of 22 microRNAs was utilised to assess microRNA expression at both time-points. Multiple logistic regression was used to develop models which were compared to conventional prognostic models using the DeLong method.

Results: Individual microRNAs confer limited prognostic value when utilised in isolation. However, incorporating them within microRNA-based outcome prediction models increases their clinical utility. Our early time-point model (AUC = 0.78, 95% CI 0.71-0.84) contained a microRNA signature associated with liver regeneration and our late time-point model (AUC = 0.83, 95% CI 0.76-0.89) contained a microRNA signature associated with cell-death. Both models were enhanced when combined with model for end-stage liver disease (MELD) score and vasopressor use and both outperformed the King's College criteria. The early time-point model combined with clinical parameters outperformed the ALF Study Group prognostic index and the MELD score.

Conclusions: Our findings demonstrate that a regeneration-linked microRNA signature combined with readily available clinical parameters can outperform existing prognostic models for ALF in identifying patients with poor prognosis who may benefit from transplantation.

Lay summary: While acute liver failure can be reversible, some patients will die without a liver transplant. We show that blood test markers that measure the potential for liver recovery may help improve identification of patients unlikely to survive acute liver failure who may benefit from a liver transplant.

Keywords: Regeneration; biomarker; cell-death; outcome prediction.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.

Figures

**Fig. 1.. Heat map and 2-way hierarchical clustering of miRNA expression in both outcome groups at both time-points.**
Clustering was performed on all samples and on the top 16 miRNAs with the highest SD using dCq values (miRNA were excluded if not detected in greater than 100 samples). dCq, delta quantification cycle; miR/miRNA, microRNA.

**Fig. 2.. The early time-point miRNA-based model.**
(A) miRNA included within the model. (B) Model performance (n = 182; AUC 0.78 [95% CI 0.71–0.84; p <0.0001*]; pseudo r2 = 0.2213; HL statistic 12.67 [*p =* 0.12]). (C) MetaCore^™ pathway analysis including all miRNA within the model. (D) MetaCore^™ pathway analysis including miRNA within both time-point models (miR-149 and −191) (E) MetaCore^™ pathway analysis including miRNA only within the early time-point model (miR-20a, −27a, −150). (E) Comparisons with other outcome prediction models with and without threshold values using the DeLong method. Statistical significance set as per Benjamini-Hochberg procedure with a false discovery rate of 0.05 (*p <0.026). ALFSGPI, Acute Liver Failure Study Group prognostic index; HL, Hosmer-Lemeshow; KCC, King’s College criteria; MELD, model for end-stage liver disease; miR/miRNA, microRNA; OR, odds ratio.

**Fig. 3.. The late time-point miRNA-based model.**
(A) miRNA included within the model. (B) Model performance (n = 175; AUC 0.83 [95% CI 0.76–0.89; p <0.0001*]; pseudo r2 = 0.2767, HL statistic 11.54 [*p =* 0.17]). (C) MetaCore^™ pathway analysis including miRNA within the model. (D) Comparisons with other outcome prediction models with and without threshold values using the DeLong method. Statistical significance set as per Benjamini-Hochberg procedure with a false discovery rate of 0.05 (*p <0.026). ALFSGPI, Acute Liver Failure Study Group prognostic index; HL, Hosmer-Lemeshow; KCC, King’s College criteria; MELD, model for end-stage liver disease; miR/miRNA, microRNA; OR, odds ratio.

**Fig. 4.. Comparing the performances of the early and late time-point models.**
(A) Performance of the late time-point model at the early time-point (n = 167; AUC 0.54; 95% CI 0.45–0.63; *p =* 0.40). (B) Performance of the early time-point model at the late time-point (n = 165; AUC 0.65; 95% CI 0.56–0.73; *p =* 0.001*). (C,D) Combined model performance in patients with paired samples (n = 165; AUC 0.87 [95% CI 0.82–0.93; p <0.0001*]; pseudo r2 = 0.4153, HL statistic 14.37 [*p =* 0.07]). (E) Comparison of both models’ performances in patients with paired samples using the DeLong method. Statistical significance set as per Benjamini-Hochberg procedure with a false discovery rate of 0.05 (*p <0.026). HL, Hosmer-Lemeshow; OR, odds ratio.

**Fig. 5.. Combining the models with clinical parameters.**
(A) Early time-point model adjusted for MELD and vasopressor use. (B) Late time-point model adjusted for MELD and vasopressor use. (C) Early time-point model performance (n = 177; AUC 0.83 [95% CI 0.78–0.89; p <0.0001*], pseudo r2 = 0.3396, HL statistic 6.83 [*p =* 0.56]). (D) Late time-point model performance (n = 149; AUC 0.91 [95% CI 0.86–0.96; p <0.0001*), pseudo r2 = 0.5290, HL statistic = 6.74 (*p =* 0.57)). (E,F) Comparing the early (E) and late (F) time-point models with clinical parameters integrated (with and without threshold values) to other commonly used outcome prediction models using the DeLong method. Statistical significance set as per Benjamini-Hochberg procedure with a false discovery rate of 0.05 (*p <0.026). ALFSGPI, Acute Liver Failure Study Group prognostic index; HL, Hosmer-Lemeshow; KCC, King’s College criteria; MELD, model for end-stage liver disease; OR, odds ratio.

See this image and copyright information in PMC

References

1. O’Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet 1993;342:273–275. - PubMed
1. Reuben A, Tillman H, Fontana RJ, Davern T, McGuire B, Stravitz RT, et al. Outcomes in adults with acute liver failure between 1998 and 2013: an observational cohort study. Ann Intern Med 2016;164:724–732. - PMC - PubMed
1. Bernal W, Hyyrylainen A, Gera A, Audimoolan VK, McPhail MJW, Auzinger G, et al. Lessons from look-back in acute liver failure? A single centre experience of 3300 patients. J Hepatol 2013;59:74–80. - PubMed
1. O’Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439–445. - PubMed
1. Koch DG, Tillman H, Durkalski V, Lee WM, Reuben A. Development of a model to predict transplant-free survival of patients with acute liver failure. Clin Gastroenterol Hepatol 2016;14:1199–1206.e2. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

A novel microRNA-based prognostic model outperforms standard prognostic models in patients with acetaminophen-induced acute liver failure

Collaborators

Affiliations

A novel microRNA-based prognostic model outperforms standard prognostic models in patients with acetaminophen-induced acute liver failure

Authors

Collaborators

Affiliations

Abstract

Conflict of interest statement

Figures

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources